Rigel Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is -10.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 13.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation B+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 2.5x | Better than 99% |
| Forward P/E | 12.0x | Better than 68% |
| Price / Sales | 2.9x | Better than 43% |
| P/E vs own 5-yr range | 70th pctl | Better than 37% |
Growth A+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 34.8% | Better than 92% |
| Free cash flow CAGR (3Y) | 80.9% | Better than 91% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 93.3% | Better than 98% |
| Operating margin | 42.6% | Better than 96% |
| Net margin | 124.7% | Better than 100% |
| Return on equity | 185.9% | Better than 98% |
| Return on invested capital | 145.6% | Better than 100% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -12.6% | Better than 45% |
| 6-month return | 38.2% | Better than 93% |
| 12-month return (ex latest month) | 4.1% | Better than 39% |
| Distance below 52-week high | 23.8% | Better than 53% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.4x | Better than 65% |
| Debt to assets | 10.4% | Better than 69% |
| Interest coverage | 17.6x | Better than 81% |
| Free cash flow / net income | 20.6% | Better than 6% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 50.0% | Better than 26% |
| Upside to average target | 66.5% | Better than 75% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 41.19
- Open
- 40.65
- Day range
- 39.62 - 41.66
- Avg price
- 40.26
- Volume
- 352.23K
- Turnover
- 14.18M
- Turnover ratei
- 2.33%
- Volume ratioi
- 1.48
- Amplitudei
- 4.96%
- 52-week rangei
- 24.95 - 52.61
Valuation
- P/Ei
- 2.06
- P/E (TTM)i
- 2.49
- P/Bi
- 1.70
- EPSi
- 19.48
- Book value / shi
- 23.64
- Net profit
- 366.81M
- Net assets
- 445.10M
Share structure
- Market cap
- 754.89M
- Float capi
- 606.40M
- Shares out
- 18.83M
- Float sharesi
- 15.13M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
23.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+2.11M net over the window
Short interest
- Shares short
- 2.54M
- % of floati
- 13.57%
- Days to coveri
- 12.93
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
Rigel Pharmaceuticals last traded at 40.09. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Rigel Pharmaceuticals's market cap?
About 754.89M.
What is the P/E ratio of Rigel Pharmaceuticals?
The trailing twelve-month P/E is 2.49, above its own 5-year average of 1.07 — toward the top of its historical range (70.39% percentile). See the Valuation tab for the full history.
Does Rigel Pharmaceuticals pay a dividend?
Rigel Pharmaceuticals does not currently pay a regular dividend.
Is Rigel Pharmaceuticals a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 66.75, which implies 66.5% upside from the current price. This is not investment advice.
What is Rigel Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Rigel Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Rigel Pharmaceuticals discussion 0 comments